{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:32:56Z","timestamp":1792038776855,"version":"4.4.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Mortimer B. Zuckerman STEM Leadership Program and the Breast Cancer Research Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Approximately one in six women in the USA takes antidepressants and a third use selective serotonin reuptake inhibitors (SSRIs) after breast cancer diagnosis. Recent investigation demonstrated serotonin receptor (5-HTR2B) expression in the breast and serotonin production as an indicator of poor breast cancer prognosis. This study investigates the association between SSRI use at different time intervals relative to breast cancer diagnosis on survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A population-based sample of 6959 consecutive, newly diagnosed breast cancer cases in Northern Israel was included. Patients were recruited from January 2000 and followed up through March 2020. Participants completed risk factor questionnaires regarding medical, reproductive and family history, medication use and health habits. Full prescription data were available through the Israeli national Clalit medical database. Multivariate Cox proportional hazard models were used to determine survival based on time of SSRI use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Use of SSRIs in the 5\u2009years prior to breast cancer diagnosis was associated with a 66% increase in overall mortality (HRadj \u2009=\u20091.66; CI: 1.05\u20132.63). SSRI use that initiated after breast cancer diagnosis was associated with an 81% increase in mortality (HRadj\u2009=\u20091.81; CI: 1.58\u20132.06). Use of SSRIs in the 5\u2009years post-diagnosis was associated with a dose\u2013response increase (P\u2009&amp;lt;\u20090.001) in long-term mortality (&amp;gt;5\u2009years). Heavy SSRI use (\u226524 prescription fills) after diagnosis was associated with nearly doubling in mortality (HR\u2009=\u20091.99; CI: 1.39\u20132.83).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SSRI use prior to and after breast cancer diagnosis is associated with increased mortality in breast cancer patients. Additional research is needed to better understand mechanisms mediating this association.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ije\/dyac004","type":"journal-article","created":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T07:06:32Z","timestamp":1642316792000},"page":"807-816","source":"Crossref","is-referenced-by-count":21,"title":["Selective serotonin reuptake inhibitors associated with increased mortality risk in breast cancer patients in Northern Israel"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1710-0863","authenticated-orcid":false,"given":"Avital","family":"Fischer","sequence":"first","affiliation":[{"name":"Department of Community Medicine and Epidemiology, Carmel Medical Center and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology and Clalit National Cancer Control Center , Haifa, Israel"},{"name":"Zuckerman STEM Post-Doctoral Fellowship Program, Zuckerman Institute, Tel Aviv, Israel"},{"name":"School of Medicine, University of California, Medical Scientist Training Program , Irvine, CA, USA"},{"name":"Department of Psychiatry and Behavioral Sciences, Stanford University , CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedy S","family":"Rennert","sequence":"additional","affiliation":[{"name":"Department of Community Medicine and Epidemiology, Carmel Medical Center and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology and Clalit National Cancer Control Center , Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8512-068X","authenticated-orcid":false,"given":"Gad","family":"Rennert","sequence":"additional","affiliation":[{"name":"Department of Community Medicine and Epidemiology, Carmel Medical Center and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology and Clalit National Cancer Control Center , Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"2022061309582411200_dyac004-B1","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1158\/1055-9965.EPI-15-0535","article-title":"International variation in female breast cancer incidence and mortality rates","volume":"24","author":"DeSantis","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2022061309582411200_dyac004-B2","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"key":"2022061309582411200_dyac004-B3","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1126\/science.343.6178.1452","article-title":"Breast cancer: a world of differences","volume":"343","author":"Servick","year":"2014","journal-title":"Science"},{"key":"2022061309582411200_dyac004-B4","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/bmj.38343.670868.D3","article-title":"Depression and anxiety in women with early breast cancer: five year observational cohort study","volume":"330","author":"Burgess","year":"2005","journal-title":"BMJ"},{"key":"2022061309582411200_dyac004-B5","first-page":"25","article-title":"Use of antidepressants: expansion beyond depression and anxiety","author":"Cascade","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"key":"2022061309582411200_dyac004-B6","year":"2017"},{"key":"2022061309582411200_dyac004-B7","first-page":"1","article-title":"Antidepressant use among persons aged 12 and over: United States, 2011-2014","volume":"283","author":"Pratt","year":"2017","journal-title":"NCHS Data Brief"},{"key":"2022061309582411200_dyac004-B8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/026988119701100410","article-title":"Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission","volume":"11","author":"Cowen","year":"1997","journal-title":"J Psychopharmacol"},{"key":"2022061309582411200_dyac004-B9","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/jnci\/djg108","article-title":"Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine","volume":"95","author":"Stearns","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2022061309582411200_dyac004-B10","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Abe","year":"2011","journal-title":"Lancet"},{"key":"2022061309582411200_dyac004-B11","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s12253-019-00734-w","article-title":"Serotonin and dopamine receptor expression in solid tumours including rare cancers","volume":"26","author":"Peters","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"2022061309582411200_dyac004-B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep19771","article-title":"Generation of 2,000 breast cancer metabolic landscapes reveals a poor prognosis group with active serotonin production","volume":"6","author":"Leoncikas","year":"2016","journal-title":"Sci Rep"},{"key":"2022061309582411200_dyac004-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-017-0928-0","article-title":"Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study","volume":"20","author":"Busby","year":"2018","journal-title":"Breast Cancer Res"},{"key":"2022061309582411200_dyac004-B14","doi-asserted-by":"crossref","first-page":"e12666","DOI":"10.1111\/ecc.12666","article-title":"Chronic therapy with selective serotonin reuptake inhibitors and survival in newly diagnosed cancer patients","volume":"27","author":"Boursi","year":"2018","journal-title":"Eur J Cancer Care"},{"key":"2022061309582411200_dyac004-B15","doi-asserted-by":"crossref","first-page":"c693","DOI":"10.1136\/bmj.c693","article-title":"Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study","volume":"340","author":"Kelly","year":"2010","journal-title":"BMJ"},{"key":"2022061309582411200_dyac004-B16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djv337","article-title":"Tamoxifen and antidepressant drug interaction among a cohort of 16 887 breast cancer survivors","volume":"108","author":"Haque","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"2022061309582411200_dyac004-B17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10549-007-9828-9","article-title":"Breast cancer recurrence risk in relation to antidepressant use after diagnosis","volume":"112","author":"Chubak","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"2022061309582411200_dyac004-B18","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12282-018-0914-0","article-title":"Does breast cancer growth rate really depend on tumor subtype? Measurement of tumor doubling time using serial ultrasonography between diagnosis and surgery","volume":"26","author":"Nakashima","year":"2019","journal-title":"Breast Cancer"},{"key":"2022061309582411200_dyac004-B19","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1002\/cncr.30688","article-title":"Effect of depression before breast cancer diagnosis on mortality among postmenopausal women","volume":"123","author":"Liang","year":"2017","journal-title":"Cancer"},{"key":"2022061309582411200_dyac004-B20","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1158\/1078-0432.CCR-16-0547","article-title":"Oral bisphosphonates and improved survival of breast cancer","volume":"23","author":"Rennert","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2022061309582411200_dyac004-B21","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1200\/JCO.2010.28.1113","article-title":"Use of bisphosphonates and risk of postmenopausal breast cancer","volume":"28","author":"Rennert","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022061309582411200_dyac004-B22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic in longitudinal studies: development","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2022061309582411200_dyac004-B23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/pon.4037","article-title":"The association of mood disorders with breast cancer survival: an investigation of linked cancer registration and hospital admission data for South East England","volume":"25","author":"Kanani","year":"2016","journal-title":"Psychooncology"},{"key":"2022061309582411200_dyac004-B24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1176\/appi.psy.44.1.24","article-title":"Depression as a prognostic factor for breast cancer mortality","volume":"44","author":"Hjerl","year":"2003","journal-title":"Psychosomatics"},{"key":"2022061309582411200_dyac004-B25","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1532-5415.2004.52018.x","article-title":"Effect of depression on diagnosis, treatment, and survival of older women with breast cancer","volume":"52","author":"Goodwin","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"2022061309582411200_dyac004-B26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2190\/0C63-U15V-5NUR-TVXE","article-title":"The effects of major depression and phobia on stage at diagnosis of breast cancer","volume":"29","author":"Desai","year":"1999","journal-title":"Int J Psychiatry Med"},{"key":"2022061309582411200_dyac004-B27","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jama.285.7.885","article-title":"Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older","volume":"285","author":"Yancik","year":"2001","journal-title":"JAMA"},{"key":"2022061309582411200_dyac004-B28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jad.2017.06.009","article-title":"Multimorbidity and depression: a systematic review and meta-analysis","volume":"221","author":"Read","year":"2017","journal-title":"J Affect Disord"},{"key":"2022061309582411200_dyac004-B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr2448","article-title":"Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival","volume":"11","author":"Pai","year":"2009","journal-title":"Breast Cancer Res"},{"key":"2022061309582411200_dyac004-B30","doi-asserted-by":"crossref","first-page":"e0138134","DOI":"10.1371\/journal.pone.0138134","article-title":"Cancer mortality in people treated with antidepressants before cancer diagnosis: a population based cohort study","volume":"10","author":"Sun","year":"2015","journal-title":"PLoS One"},{"key":"2022061309582411200_dyac004-B31","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10549-012-2330-z","article-title":"Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010","volume":"137","author":"Dusetzina","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"2022061309582411200_dyac004-B32","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/pds.1719","article-title":"Antidepressant medication use and breast cancer risk","volume":"18","author":"Wernli","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["International Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ije\/article-pdf\/51\/3\/807\/44036584\/dyac004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ije\/article-pdf\/51\/3\/807\/44036584\/dyac004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T06:06:34Z","timestamp":1655100394000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ije\/article\/51\/3\/807\/6521337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2,3]]},"published-print":{"date-parts":[[2022,6,13]]}},"URL":"https:\/\/doi.org\/10.1093\/ije\/dyac004","relation":{},"ISSN":["0300-5771","1464-3685"],"issn-type":[{"value":"0300-5771","type":"print"},{"value":"1464-3685","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,2,3]]}}}